Human Drug Compounding Under
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic
Act
Extension without change of a currently approved collection
No
Regular
03/27/2026
Requested
Previously Approved
36 Months From Approved
03/31/2026
17,191
17,191
8,960
8,944
0
0
This information collection supports
implementation of Sections 503A and 503B of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) - which governs pharmacy
compounding and outsourcing facilities. The requirements include
reporting, recordkeeping, and disclosures.
While we have retained our
currently approved burden estimates, we have corrected several
inadvertent errors. We added more precision to the number of
responses per respondent figures in rows 3 and 6; corrected the
average burden per response in row 6 (from 0.2 to 0.025 hour (1.5
mins.)); and corrected the total hours calculation in rows 3, 6,
and 7. Due to these corrections, we have adjusted our total burden
estimate upward by 16 hours (from 8,944 to 8,960) annually.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
03/27/2026
Something went wrong when
downloading this file. If you have any questions, please send an
email to [email protected].